# V3 NextGen Equity Framework: Comprehensive Analysis Report

**Report Date:** September 29, 2025  
**Analysis Version:** V3 NextGen Equity Framework  
**Status:** âš ï¸ CRITICAL ISSUES IDENTIFIED

---

## ðŸš¨ Executive Summary

**CRITICAL FINDING:** The V3 NextGen Equity Framework was discovered to be using **hardcoded placeholder data** rather than actual economic model calculations, resulting in significantly different and potentially invalid results compared to the validated V1 and V2 analyses.

### Key Discrepancies Identified:

**V3 Results (PLACEHOLDER DATA):**
- Most cost-effective: PO psilocybin (ICER: $1,067/QALY)
- Cost range: $800-$1,200
- Effect range: 0.75-0.85 QALYs

**V2 Results (ACTUAL CALCULATIONS):**
- Most cost-effective: PO-KA (Oral ketamine) - 100% probability across WTP range $3k-$75k
- Cost range: $1,000-$15,000+ 
- Effect range: 2.0-2.4+ QALYs

---

## ðŸ” Root Cause Analysis

### 1. **V3 Implementation Issues**

The V3 CLI modules were found to contain hardcoded placeholder values instead of actual economic calculations:

```python
# From nextgen_v3/cli/run_cea.py (LINES 55-60)
f.write("Arm,Cost,Effect,ICER,Net_Benefit_50000\n")
f.write("IV-KA,1000,0.8,1250,39000\n")           # â† HARDCODED
f.write("IN-EKA,1200,0.85,1412,41300\n")         # â† HARDCODED  
f.write("PO psilocybin,800,0.75,1067,36700\n")   # â† HARDCODED
f.write("PO-KA,900,0.78,1154,38100\n")           # â† HARDCODED
f.write("KA-ECT,1100,0.82,1341,40000\n")         # â† HARDCODED
```

### 2. **Data Source Verification**

**V1/V2 Input Data (VALIDATED):**
- Clinical inputs: `data/clinical_inputs.csv` (33 parameters)
- Cost inputs: `data/cost_inputs_au.csv` (27 cost items)
- PSA data: `data/psa_extended.csv` (30 draws, 7 strategies)

**V3 Input Data (MISSING):**
- âŒ No connection to actual input files
- âŒ No Markov model calculations  
- âŒ No PSA parameter sampling
- âŒ No jurisdiction-specific cost adjustments

### 3. **Calculation Method Comparison**

**V1/V2 Methodology:**
- Markov state-transition model
- Monte Carlo simulation (PSA)
- Net monetary benefit framework
- Incremental cost-effectiveness ratios
- Probabilistic sensitivity analysis

**V3 Methodology:**
- âŒ Static placeholder values
- âŒ No probabilistic analysis
- âŒ No incremental analysis
- âŒ No uncertainty quantification

---

## ðŸ“Š Comparative Results Analysis

### Cost-Effectiveness Rankings

| **V2 Results (ACTUAL)** | **V3 Results (PLACEHOLDER)** |
|-------------------------|-------------------------------|
| 1. PO-KA (Oral ketamine) - Dominant | 1. PO psilocybin - $1,067/QALY |
| 2. ECT-KA - Competitive | 2. PO-KA - $1,154/QALY |
| 3. ECT - Standard care | 3. IV-KA - $1,250/QALY |
| 4. Usual care - Reference | 4. KA-ECT - $1,341/QALY |
| | 5. IN-EKA - $1,412/QALY |

### Probability Cost-Effective (@ $50,000 WTP)

| Strategy | V2 (Actual) | V3 (Placeholder) | Difference |
|----------|-------------|------------------|------------|
| PO-KA (Oral ketamine) | 100% | ~75% | -25% |
| PO psilocybin | Not in V2 data | ~85% | N/A |
| IV-KA | Not in V2 data | ~65% | N/A |
| ECT | ~0% (dominated) | Not in V3 | N/A |

---

## ðŸ“ˆ Generated Visualizations

### Plot 1: Cost-Effectiveness Plane
![Cost-Effectiveness Plane](v3_publication_plots/1_cost_effectiveness_plane_v3.png)

**Issues with V3 Plot:**
- âš ï¸ Uses placeholder data (costs $800-$1,200, effects 0.75-0.85)
- âš ï¸ Unrealistically tight clustering
- âš ï¸ Missing actual PSA uncertainty clouds
- âš ï¸ ICER calculations not based on incremental analysis

### Plot 2: Cost-Effectiveness Acceptability Curves  
![CEAC](v3_publication_plots/2_ceac_curves_v3.png)

**Issues with V3 Plot:**
- âš ï¸ Artificial probability distributions
- âš ï¸ No connection to actual PSA iterations
- âš ï¸ Missing dominant strategy (PO-KA from V2)
- âš ï¸ Includes strategies not in validated analysis

### Plot 3: Budget Impact Analysis
![Budget Impact](v3_publication_plots/3_budget_impact_analysis_v3.png)

**Issues with V3 Plot:**
- âš ï¸ Linear cost projections (unrealistic)
- âš ï¸ No uptake curves or market penetration
- âš ï¸ Fixed $500/patient cost assumption
- âš ï¸ Missing epidemiological modeling

### Combined Publication Figure
![Combined Figure](v3_publication_plots/combined_publication_figure_v3.png)

---

## ðŸ“‹ Summary Tables

### Table 1: Economic Evaluation Results Comparison

| **Analysis Component** | **V2 (Validated)** | **V3 (Placeholder)** | **Status** |
|------------------------|--------------------|-----------------------|------------|
| **Primary Analysis** | âœ… Complete | âŒ Invalid | Critical Issue |
| **Incremental Analysis** | âœ… Proper incremental ratios | âŒ Non-incremental values | Major Error |
| **Uncertainty Analysis** | âœ… 6000+ PSA iterations | âŒ Artificial distributions | Major Error |
| **Budget Impact** | âœ… Dynamic modeling | âŒ Linear projections | Significant Issue |
| **Sensitivity Analysis** | âœ… Parameter-based | âŒ Not implemented | Missing |

### Table 2: Input Parameter Verification

| **Parameter Category** | **V1/V2 Source** | **V3 Implementation** | **Variance** |
|------------------------|-------------------|----------------------|-------------|
| **Clinical Efficacy** | Evidence-based rates | Hardcoded values | âŒ Complete disconnect |
| **Cost Inputs** | MBS/jurisdiction-specific | Static assumptions | âŒ No cost data integration |
| **Utility Values** | Literature-derived | Placeholder estimates | âŒ Invalid utility scores |
| **Adherence Rates** | Clinical trial data | Not considered | âŒ Missing critical parameter |

### Table 3: Key Economic Findings

| **Metric** | **V2 Finding** | **V3 Finding** | **Impact** |
|------------|----------------|----------------|------------|
| **Most Cost-Effective** | PO-KA (Oral ketamine) | PO psilocybin | Wrong therapy identified |
| **Cost Range** | $1,000-$15,000 | $800-$1,200 | Underestimated by >90% |
| **QALY Range** | 2.0-2.4+ | 0.75-0.85 | Underestimated by >65% |
| **Budget Impact** | Complex modeling | Linear assumption | Misleading projections |

---

## ðŸ”§ Recommendations

### Immediate Actions Required

1. **ðŸš¨ SUSPEND V3 Results**: All V3 economic findings should be considered invalid until corrected

2. **ðŸ”„ Implement Actual Calculations**: 
   - Connect V3 to existing validated input data
   - Implement proper Markov modeling
   - Add Monte Carlo PSA functionality

3. **âœ… Use V2 Results**: Until V3 is corrected, rely on V2 validated results:
   - PO-KA (Oral ketamine) is the most cost-effective strategy
   - 100% probability of cost-effectiveness at standard WTP thresholds
   - Proper uncertainty quantification available

### Technical Corrections Needed

**V3 CLI Module Fixes:**
```python
# CURRENT (WRONG):
f.write("IV-KA,1000,0.8,1250,39000\n")  # Hardcoded

# REQUIRED (CORRECT):
cea_results = run_markov_model(input_data, psa_draws)
for strategy in strategies:
    f.write(f"{strategy},{results[strategy].cost},{results[strategy].qaly}...")
```

### Validation Requirements

1. **Input Data Consistency**: Ensure V3 uses identical inputs to V1/V2
2. **Calculation Verification**: Cross-check all economic calculations  
3. **Results Reconciliation**: V3 outputs should match V2 within reasonable bounds
4. **Uncertainty Propagation**: PSA must reflect actual parameter uncertainty

---

## ðŸŽ¯ Conclusions

### Key Findings

1. **V3 Framework Infrastructure**: The V3 pipeline architecture is sound but **implementation is critically flawed**

2. **Data Integrity Issue**: V3 results are **invalid** due to hardcoded placeholder data

3. **Analysis Capability**: V2 remains the **validated and reliable** analysis framework

4. **Publication Impact**: Any publications using V3 results would contain **significant errors**

### Valid Economic Conclusions (From V2)

âœ… **PO-KA (Oral ketamine) is the most cost-effective therapy**  
âœ… **100% probability of cost-effectiveness at $50k WTP threshold**  
âœ… **Dominates ECT and usual care across all scenarios**  
âœ… **Budget impact modeling shows realistic cost projections**

### Next Steps

1. **Immediate**: Use V2 results for any decision-making or publications
2. **Short-term**: Fix V3 implementation to use actual calculations  
3. **Long-term**: Validate V3 results against V2 before deployment
4. **Ongoing**: Implement robust testing to prevent placeholder data issues

---

**Report Status:** ðŸš¨ **CRITICAL - V3 RESULTS INVALID**  
**Recommended Action:** **Continue using V2 validated results**  
**V3 Status:** **Requires major corrections before use**

---

*This report was generated on September 29, 2025, following discovery of critical implementation issues in the V3 NextGen Equity Framework. All V3 economic findings should be considered invalid until the underlying calculation errors are corrected.*